[Federal Register Volume 90, Number 3 (Monday, January 6, 2025)]
[Notices]
[Page 596]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-31702]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B-62-2024]


Foreign-Trade Zone (FTZ) 49, Notification of Proposed Production 
Activity; Sanofi US Services Inc.; (Pharmaceutical Products); 
Ridgefield, New Jersey

    Sanofi US Services Inc. submitted a notification of proposed 
production activity to the FTZ Board (the Board) for its facilities in 
Ridgefield, New Jersey within FTZ 49. The notification conforming to 
the requirements of the Board's regulations (15 CFR 400.22) was 
received on December 18, 2024.
    Pursuant to 15 CFR 400.14(b), FTZ production activity would be 
limited to the specific foreign-status material(s)/component(s) and 
specific finished product(s) described in the submitted notification 
(summarized below) and subsequently authorized by the Board. The 
benefits that may stem from conducting production activity under FTZ 
procedures are explained in the background section of the Board's 
website--accessible via www.trade.gov/ftz.
    The proposed finished product is Beyfortus[supreg] (Nirsevimab)--
dosage form vaccine (duty-free).
    The proposed foreign-status materials/components include 
Beyfortus[supreg] (Nirsevimab monoclonal antibody active pharmaceutical 
ingredient)--unmixed and mixed drug substance (duty-free).
    Public comment is invited from interested parties. Submissions 
shall be addressed to the Board's Executive Secretary and sent to: 
[email protected]. The closing period for their receipt is February 18, 
2025.
    A copy of the notification will be available for public inspection 
in the ``Online FTZ Information System'' section of the Board's 
website.
    For further information, contact Diane Finver at 
[email protected].

    Dated: December 31, 2024.
Elizabeth Whiteman,
Executive Secretary.
[FR Doc. 2024-31702 Filed 1-3-25; 8:45 am]
BILLING CODE 3510-DS-P